What You Should Know:– COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers.– Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Enhancing Cancer Care with AI and Real-World DataElectronic health records contain a comprehensive account of a patient’s cancer care journey. However, their unstructured and incomplete format poses challenges for analysis. By infusing AI into data processing, COTA and Precision Health Informatics (PHI) aim to accelerate precision medicine at the point of care.Founded by oncologists, COTA focuses on precise, patient-first cancer care using real-world data. Their advanced analytics platform partners with life sciences companies, providers, and payers to improve cancer treatment. Learn more at cotahealthcare.com.Dr. C.K

What You Should Know:– A collaborative effort between COTA, PreciseDx, and Baptist Health South Florida seeks to revolutionize breast cancer recurrence risk assessment with the PreciseBreast™ (PDxBr) test. This AI-powered tool holds promise for faster, more accurate, and more affordable risk prediction compared to current methods.– By utilizing AI technology, PreciseBreast™ has the potential to offer patients a faster, more accurate, and more affordable way to assess their risk of recurrence and make informed treatment decisions in collaboration with their physicians.The Challenge of Breast Cancer RecurrenceOne in eight women in the US will face a breast cancer diagnosis in their lifetime. Understanding a patient’s specific risk of recurrence is crucial for informing treatment decisions. While existing gene-expression tests offer some insights, they have limitations:Limited Accuracy: Current testing methods may not capture the full picture of recurrence risk.Current testing methods may not capture the full picture of recurrence risk. High Cost: Gene-expression tests can be expensive, potentially limiting access for some patients.Gene-expression tests can be expensive, potentially limiting access for some patients. Delayed Results: Waiting two to four weeks for test results can delay critical treatment decisions.PreciseDx Aims to Transform Risk AssessmentPreciseDx’s PreciseBreast™ test utilizes artificial intelligence (AI) to analyze pathology slide images

NEW YORK--(BUSINESS WIRE)--Today, COTA announced an extension of its research collaboration with ​​the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence. Under the collaboration, the two organizations will continue to jointly develop and implement research projects to advance the use of real-world data (RWD) and explore the potential strengths and limitations of using real-world evidence (RWE) for regulatory purposes. This collaboration serves as an extension of the agreement between COTA and the FDA established in 2018. To date, the partnership has yielded numerous oncology research studies that have been presented at the annual meetings of the American Society of Hematology (ASH) and the American Association of Cancer Research (AACR). The collaboration has been extended for an additional 5 years, focusing on leveraging real-world evidence to strengthen regulatory decision-making